
Bortenat 2mg Injection
Salt Composition: Bortezomib
Expiry Date: 01/2028
Inclusive of all taxes
1 Injection
About The Product
Multiple myeloma
Mantle-cell lymphoma and multiple myeloma can be treated with Bortenat 2mg injections. By inhibiting or reducing the proliferation of cancer cells, it displays its efficacy. Only a physician or a qualified nurse can administer an intravenous injection of Boratenat 2mg. It contains Bortezomib(2mg) in composition.
Uses
Multiple myeloma
Mantle-cell lymphoma
Side Effects
- Most side effects of Bortenat 2mg injection do not require medical attention as they may disappear as your body adjusts to the medicine.
- In case these side effects become worse, consult your doctor immediately. Dizziness Tingling of hands and arms Sore throat Shortness of breath Increased bleeding Fever Chills Wheezing Muscle cramps Constipation Nausea Vomiting Loss of appetite Stomach pain
Dosage and Administration
- Bortenat 2mg injection is a prescription-based medication that should be injected intravenously by a doctor or an experienced nurse.
- In case of an overdose of Bortenat, contact your doctor or any healthcare provider and seek medical attention immediately
Mechanism of action
Bortenat 2mg injection is a dipeptide boronic acid derivative that functions as a proteasome inhibitor. It interferes with the functioning of the 26S proteasome, which furthermore causes apoptosis in cancerous cells.
Additionally, it arrests the cell cycle in the middle. Bortenat suppresses the NF–κB signaling pathway, which is associated with anti-apoptotic genes.
Thus, Bortenat 2mg suppresses the tumours progressively.
Safety Advice
Missed Doses
- It is advisable not to miss any dose.
- In case you miss a dose of Bortenat 2mg injection consult your doctor soon.
- Missing the dose will impact the overall health of the patients.
- So, it is always advisable to follow the prescription of the doctor strictly.
FAQs
Bortenat 2mg injection/vial is an anticancer injection that is primarily used in the treatment of multiple myeloma.
Reference
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Richardson, P. G. (2008). Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. New England Journal of Medicine, 359(9), 906–917. https://doi.org/10.1056/NEJMoa0801479.
Bortezomib‐containing regimens are effective in multiple myeloma—results of a non-interventional study. Phase IV (2015). Blood Cancer Journal. https://doi.org/10.1038/srep06944
Bortezomib therapy in a real-world setting in patients with relapsed or refractory multiple myeloma. (2019). Translational Cancer Research, 8(6), 2019. https://doi.org/10.21037/tcr.2019.09.18
Real-world medical practice use of bortezomib-based therapy in RRMM: the VELCADE® Observational Study. (2018). Clinical Lymphoma, Myeloma & Leukemia, 18(4), e205–e212. https://doi.org/10.1016/j.clml.2018.03.010
Medical Disclaimer
Accurate, reviewed information to support informed healthcare decisions
Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.
The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.
This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.
Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.
.jpeg%3FupdatedAt%3D1763121181831&w=128&q=75)
